The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Directors buying.
Also the crooked MM's and the way the small cap market is run, any weakness in share price is manipulated, mm's will be taking every opportunity to steal these cheap shares.
Traded Action Notifier Price Currency Amount Holding
16-Apr-24 15-Apr-24 Buy Kim Suter 19.78 GBX 4,828 31,494
16-Apr-24 15-Apr-24 Buy Dan Carter 27.98 GBX 1,757 6,757
16-Apr-24 15-Apr-24 Buy Garry Jones 24.84 GBX 100,000
Directors Bought
Director Dealings
KRM22 plc, (AIM: KRM) the technology and software investment company that focuses on risk management for capital markets, announces that on 15 April 2024, certain Directors of the Company have purchased ordinary shares.
Excellent rns
KRM22 said: "seven of the top 15 largest FCMs are now contracted to use the Limits Manager product, both direct with KRM22 and through the sales channel with Trading Technologies International Inc."
KRM22 PLC shares were up on Monday, after the company said that its latest contract had further consolidated its dominance of the future commission merchants market.
The London-based technology and software company aims to help capital markets companies reduce the cost and complexity of risk management through its range of services.
KRM22 shares were up 46% to 27.70 pence each in London on Monday morning.
This followed the signing of a three-year contract worth GBP600,000 with an unnamed "major [FCM] company" for the use of the company's Limits Manager product.
As a result of this latest deal, KRM22 said: "seven of the top 15 largest FCMs are now contracted to use the Limits Manager product, both direct with KRM22 and through the sales channel with Trading Technologies International Inc."
Chief Executive Officer Dan Carter said: "This contract win further demonstrates that the Limits Manager product has become a firmly established product within the FCM community. In addition, the growth in annual recurring revenue to GBP6.0 million is
Rns out. Directors paid 43p.
Https://total-market-solutions.com/2024/03/rua-life-sciences-plc-2/